Acadia Investor Relations Guide to Company Information

Acadia Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing small molecule drugs for the treatment of central nervous system disorders.

The company's headquarters is located in San Diego, California, and it has a global presence with operations in several countries.

Acadia Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol ACAD.

The company's main products include pimavanserin, which is used to treat psychosis in patients with Parkinson's disease, and amisulpride, which is used to treat schizophrenia.

Acadia Companies is a significant player in the healthcare industry, specializing in behavioral healthcare services. Founded in 2005, the company has grown through strategic acquisitions and organic expansion to become a leading force in the mental health sector.

Acadia operates a wide array of facilities, including inpatient psychiatric hospitals, residential treatment centers, outpatient clinics, and therapeutic school-based programs. These establishments offer a range of services such as substance abuse treatment, mental health counseling, and specialized programs for various psychological disorders.

The company's revenue model is primarily driven by patient service revenues, which are largely paid through a mix of government programs like Medicare and Medicaid, private insurance, and direct patient payments. Acadia benefits from various streams of reimbursement, navigating the complexities of healthcare payment systems while ensuring access to care.

Here are some key updates on Acadia's recent performance:

ACADIA Pharmaceuticals Inc has carved a niche as a trailblazer in tackling neurological and central nervous system disorders. Its flagship product, NUPLAZID, was approved by the FDA in 2016.

The company's financial engine is fueled primarily by sales of NUPLAZID, which has stood as a steady pillar in generating revenues. NUPLAZID was designed to address the psychosis associated with Parkinson’s disease.

ACADIA emphasizes expanding NUPLAZID's usability through rigorous clinical trials aimed at securing approvals for additional indications. This is a key strategy for amplifying its growth trajectory.

The company actively explores partnerships and acquisitions to broaden its pipeline, inaugurating an aspirational pursuit to revolutionize mental health treatment. ACADIA Pharmaceuticals aligns its business operations not just on curing ailments, but on redefining health paradigms.

With a keen eye on demographic trends and the increasing prevalence of CNS disorders globally, ACADIA Pharmaceuticals reinforces its sustainability in the competitive biopharmaceutical landscape.

Acadia Healthcare is scheduled to participate in the Stephens 26th Annual Investment Conference, which is part of the NASH2024 event.

The conference is set to take place on November 20, 2024, at 10:00 AM.

Acadia Healthcare has been involved in various financial updates and announcements recently, including a price target adjustment by UBS to $70 from $102, maintaining a Buy rating.

Acadia has also been in the news for its expansion plans, aiming to open over 400 new beds in 2024, including more than 300 beds in the fourth quarter of 2024.

Here are some key dates related to Acadia Healthcare's recent financial updates and announcements:

Acadia Healthcare has made significant strides in the mental health and behavioral healthcare space.

The company operates over 600 behavioral healthcare facilities across the US, UK, and Australia.

Acadia's commitment to providing high-quality care is evident in its focus on treating patients with complex needs.

The company's services include inpatient and outpatient programs for mental health and substance abuse treatment.

Acadia's goal is to deliver compassionate and effective care to its patients.

Acadia's financial performance has been strong, with revenue growth exceeding $3.5 billion in 2020.

The company's focus on operational efficiency has helped drive these results.